Certain amino-substituted monocycles as kinase modulators

Details Certain amino-substituted monocycles as kinase modulators Certain amino-substituted monocycles as kinase modulators

2006-03-21

2006-03-21

Wilson, James O. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S336000

Reexamination Certificate

active

07015227

ABSTRACT:
A composition comprises a compound of Formula 1:a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein W is a nitrogen-substituted 5- or 6-membered monocyclic ring. The compounds are of utility as modulators of kinase activity.

REFERENCES:
patent: 3452018 (1969-06-01), Santilli et al.
patent: 5138058 (1992-08-01), Geisein et al.
patent: 5215990 (1993-06-01), Geisein et al.
patent: 5521184 (1996-05-01), Zimmermann
patent: 5728704 (1998-03-01), Mylari et al.
patent: 5866578 (1999-02-01), Mylari et al.
patent: 6710048 (2004-03-01), Kuo et al.
patent: 2003/0191312 (2003-10-01), Ding et al.
patent: 2004/0082627 (2004-04-01), Darrow et al.
patent: DD 83-255662 (1983-10-01), None
patent: 19700320 (1997-07-01), None
patent: 0 503 436 (1992-03-01), None
patent: 0 564 409 (1993-03-01), None
patent: 0 563 386 (1993-10-01), None
patent: 0 775 698 (1997-05-01), None
patent: 0 941 989 (1999-02-01), None
patent: 1016202 (1966-01-01), None
patent: 02-149566 (1990-06-01), None
patent: 04-049279 (1992-02-01), None
patent: WO 81/03020 (1981-10-01), None
patent: WO 96/04914 (1996-02-01), None
patent: WO 96/39400 (1996-12-01), None
patent: WO 97/03643 (1997-02-01), None
patent: WO 97/19065 (1997-05-01), None
patent: WO 98/43641 (1998-10-01), None
patent: WO 99/11633 (1999-03-01), None
patent: WO 99/31088 (1999-06-01), None
patent: WO 99/36410 (1999-07-01), None
patent: WO 00/09496 (2000-02-01), None
patent: WO 00/25780 (2000-05-01), None
patent: WO 00/59510 (2000-10-01), None
patent: WO 00/78738 (2000-12-01), None
patent: WO 01/10859 (2001-02-01), None
patent: WO 01/22938 (2001-04-01), None
patent: WO 01/25220 (2001-04-01), None
patent: WO 01/47897 (2001-07-01), None
patent: WO 01/47921 (2001-07-01), None
patent: WO 01/60806 (2001-08-01), None
patent: WO 01/87853 (2001-11-01), None
patent: WO 02/04429 (2002-01-01), None
patent: WO 02/22602 (2002-03-01), None
patent: WO 02/22610 (2002-03-01), None
patent: WO 02/060492 (2002-08-01), None
patent: WO 02/093164 (2002-11-01), None
patent: WO 02/096421 (2002-12-01), None
patent: WO 03/031406 (2003-04-01), None
patent: WO 2004/000318 (2003-12-01), None
patent: WO 2004/000820 (2004-12-01), None
Al-Dabbagh and Smith, “Species differences in oxidative drug metabolism: some basic considerations.” Archives of toxicology. Supplement. Archiv fur Toxikologie. supplement, vol. 7, pp. 219-231 (1984).
Hans Bundgaard, Design of Prodrugs, p. 1. © 1985 Elsevier Science Publishers.
Richard B. Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-400. © 1992 Academic Press, Inc.
Vippagunta et al., “Crystalline Solids” Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).
Gavezzotti, “Are Crystal Structures Predictable?” Accounts of Chemical Research, vol. 27, pp. 309-314 (1994).
International Search Report dated Jan. 18, 2004, International Application No. PCT/US03/19978, International Filing Date Jun. 23, 2003.
Courdert et al. (1988) “Synthesis and antidepressant effect of 4,6—diaryly-3-aminopyridazines, minaprine analogs,” Farmaco, Ed. Sci., 43(10):793-800 (abstract only).
Emelina et al. (1999) “Alkylhydrazines in the synthesis of 3- and 5-aminopyrazoles,” Russian Journal of Organic Chemistry (Translations of Zhurnal Organicheskoi Khimii), 35(1): 119-123 (abstract only).
Kandi et al. (1996) “New pyridasine derivatives. Effects on a biological system,” Tinctoria, 93(3): 40-49 (abstract only).
Ulrich et al. (2002) “Pacreatic Cell Lines: A Review,” (Pancreas, 24(2): 111-120.
Zayed et al. (1985) “Activated nitriles in heterocyclic synthesis. Novel synthesis of pyrazoles, pyridones and pyrrolo[2,3-b]pyridones,” Org. Prep. Proced. Int., 17(1): 70-75 (abstract only).
International Search Report dated Jan. 21, 2004, for Application No. PCT/US03/19961, International filing date Jun. 23, 2003.
International Search Report dated Oct. 9, 2003.
Wu, et al. “Chemi-and bioluminescence of coelenterazine analogues with a conjugated group at the C-8 position”, Tetrahedron Letters 42 (2001) 2997-3000.
Ding, et al. “A Combinatorial Scaffold Approach toward Kinase- Directed Heterocycle Libraries”, JACS Communications. Published on Web Feb. 2, 2002. vol. 124, No. 8, 2002. J.Am. Chem. Soc. pp. 1594-1596.
Cavalier, et al. “Catechol Derivatives of Aminopyrazine and Cell Protection Against UVB-Induced Mortality”. Bioorganic & Medicinal Chemistry 9 (2001) 1037-1044.
Stenberg, et al.; “KinMutBase, a database of human disease-causing protein kinase mutations”; Nucleic Acids Research, 2000, vol. 28, No. 1 369-371.

Affiliated with

Also associated with

Rating

Certain amino-substituted monocycles as kinase modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Certain amino-substituted monocycles as kinase modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Certain amino-substituted monocycles as kinase modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3531548